drugset / Trial / NCT07264283
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31
Phase 2
Not yet recruiting
147 enrolled
Adam Boxer
Alzheimer's Clinical Trials Consortium · collabAlzheimer's Therapeutic Research Institute · collabMassachusetts General Hospital · collabNational Institute on Aging (NIA) · collabPharmatrophiX Inc. · collabUniversity of California, San Diego · collabUniversity of Southern California · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen B will evaluate the safety and efficacy of a single study drug, LM11A-31, in participants with PSP.
Timeline
- Start
- 2026-06-30
- Primary completion
- 2030-09-28
- Completion
- 2030-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LM11A-31 | Small molecule | — | Oral |